Skip to content

Nasdaq · CIK 0000921299

KYNB KYNTRA BIO, INC.

Insider trading from SEC Form 4. Last filing 6 d ago. Close $6.11 on Oct 9, 2026, +3% from the 52-week low and -45% from the high.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
9
with a Form 4 at this company

Price and insider trades, last year

KYNBOct 9, 2026 · close 6.11

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at KYNTRA BIO, INC., scored.

ScoreInsiderValueHoldingsPrice contextFiled
42ModerateThane Wettig
CEO
buy
$34k
3,700 shares
+17%+76% from low-53% from high
53ModerateJames A Schoeneck
director
buy
$119k
23,567 shares
+146%+3% from low-73% from high
46ModerateThane Wettig
CEO
buy
$51k
145,000 shares
+36%-
43ModerateJames A Schoeneck
director
buy
$105k
300,000 shares
+407%-

Transactions

The last 37 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Oct 1, 2026Andrew E. Singer
director
AGrant or award
Stock Option (Right to Buy)derivative
+14,000$0.00$014,0006 d ago
Sep 6, 2026David DeLucia
Chief Financial Officer
FTax withholding
Common Stock
-22$8.55$1884,35533 d ago
Sep 6, 2026Thane Wettig
CEO
FTax withholding
Common Stock
-209$8.55$1,78726,79633 d ago
Mar 6, 2026David DeLucia
Chief Financial Officer
FTax withholding
Common Stock
-60$6.84$4104,429Mar 10, 2026
Mar 6, 2026Thane Wettig
CEO
FTax withholding
Common Stock
-277$6.84$1,89524,403Mar 10, 2026
Feb 3, 2026David DeLucia
Chief Financial Officer
AGrant or award
Stock Option (Right to Buy)derivative
+26,000$0.00$026,000Feb 5, 2026
Feb 3, 2026Thane Wettig
CEO
AGrant or award
Stock Option (Right to Buy)derivative
+60,000$0.00$060,000Feb 5, 2026
Dec 6, 2025David DeLucia
Chief Financial Officer
FTax withholding
Common Stock
-52$8.42$4384,489Dec 9, 2025
Dec 6, 2025Thane Wettig
CEO
FTax withholding
Common Stock
-259$8.42$2,18124,680Dec 9, 2025
Nov 13, 2025Thane Wettig
CEO
POpen-market purchase
Common Stock
+1,000$9.18$9,18022,239Nov 17, 2025
Nov 17, 2025Thane Wettig
CEO
POpen-market purchase
Common Stock
+2,700$9.10$25k24,939Nov 17, 2025
Jun 6, 2025David DeLucia
Chief Financial Officer
FTax withholding
Common Stock
-51$7.83$3994,594Sep 9, 2025
Jun 6, 2025Thane Wettig
CEO
FTax withholding
Common Stock
-246$7.83$1,92721,487Sep 9, 2025
Sep 6, 2025David DeLucia
Chief Financial Officer
FTax withholding
Common Stock
-53$12.10$6414,541Sep 9, 2025
Sep 6, 2025Thane Wettig
CEO
FTax withholding
Common Stock
-248$12.10$3,00121,239Sep 9, 2025
Jun 30, 2025James A Schoeneck
director
POpen-market purchase
Common Stockindirect: By Trust
+23,567$5.07$119k39,666Jul 2, 2025
Jun 4, 2025Jeffrey L Edwards
director
AGrant or award
Stock Option (Right to Buy)derivative
+120,000$0.00$0120,000Jun 6, 2025
Jun 4, 2025Michael Kauffman
director
AGrant or award
Stock Option (Right to Buy)derivative
+70,000$0.00$070,000Jun 6, 2025
Jun 4, 2025James A Schoeneck
director
AGrant or award
Stock Option (Right to Buy)derivative
+120,000$0.00$0120,000Jun 6, 2025
Jun 4, 2025Maykin Ho
director
AGrant or award
Stock Option (Right to Buy)derivative
+120,000$0.00$0120,000Jun 6, 2025
Jun 4, 2025Michael Kauffman
director
AGrant or award
Stock Option (Right to Buy)derivative
+120,000$0.00$0120,000Jun 6, 2025
Mar 24, 2025Thane Wettig
CEO
POpen-market purchase
Common Stock
+145,000$0.35$51k543,329Mar 25, 2025
Mar 20, 2025James A Schoeneck
director
POpen-market purchase
Common Stockindirect: By Trust
+250,000$0.35$88k323,722Mar 24, 2025
Mar 21, 2025James A Schoeneck
director
POpen-market purchase
Common Stockindirect: By Trust
+50,000$0.34$17k373,722Mar 24, 2025
Mar 6, 2025Christine Chung
SVP, CHINA OPERATIONS
FTax withholding
Common Stock
-7,008$0.39$2,733294,544Mar 7, 2025
Mar 6, 2025David DeLucia
Chief Financial Officer
FTax withholding
Common Stock
-2,325$0.39$907116,137Mar 7, 2025
Mar 6, 2025Thane Wettig
CEO
FTax withholding
Common Stock
-22,038$0.39$8,595397,915Mar 7, 2025
Mar 6, 2025Christine Chung
SVP, CHINA OPERATIONS
AGrant or award
Common Stock
+781$0.00$0295,325Mar 7, 2025
Mar 6, 2025Thane Wettig
CEO
AGrant or award
Common Stock
+781$0.00$0398,696Mar 7, 2025
Mar 6, 2025Christine Chung
SVP, CHINA OPERATIONS
FTax withholding
Common Stock
-422$0.39$165294,903Mar 7, 2025
Mar 6, 2025Thane Wettig
CEO
FTax withholding
Common Stock
-367$0.39$143398,329Mar 7, 2025
Jan 9, 2025David DeLucia
Chief Financial Officer
AGrant or award
Stock Option (Right to Buy)derivative
+525,000$0.00$0525,000Jan 10, 2025
Jan 9, 2025Thane Wettig
CEO
AGrant or award
Stock Option (Right to Buy)derivative
+1,300,000$0.00$01,300,000Jan 10, 2025
Dec 6, 2024Christine Chung
SVP, CHINA OPERATIONS
FTax withholding
Common Stock
-2,792$0.34$955301,552Dec 9, 2024
Dec 6, 2024Thane Wettig
CEO
FTax withholding
Common Stock
-2,363$0.34$808419,953Dec 9, 2024
Dec 6, 2024Juan Graham
CHIEF FINANCIAL OFFICER
FTax withholding
Common Stock
-1,446$0.34$495165,929Dec 9, 2024
Dec 7, 2024Juan Graham
CHIEF FINANCIAL OFFICER
FTax withholding
Common Stock
-1,066$0.34$365164,863Dec 9, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.